FierceBiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:38:00时区推断·⟳ 抓取 22:24:38·⚡ 决策 07-16 22:34:15 +9m37s·102.8 天前
诺诚健华Soficitinib白癜风II期达到主要终点
事件本身偏正面：Soficitinib在非节段型白癜风II/III研究的II期部分达到主要终点，且公司称安全性良好、将推进III期。
📄 原文FierceBiotech↗ 原文
A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint,…
不做 诺诚健华（09969.HK）
白癜风II期成功方向偏正面但仍早期，短期无收入兑现；同一分子AD III期成功已先于本事件发布且股价近20日已涨约35%，下一交易日追高edge不足，不做。
不做 诺诚健华（688428.SH）
A股同一主体受益逻辑一致，但科创板盘后无法成交、近20日已涨约31%，且白癜风II期相对AD III期只是增量适应症确认，追高性价比不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司先发布同一分子Soficitinib在特应性皮炎III期达到主要终点，这是更接近商业化的主催化。市场反应:09969.HK近20日+35.04%，688428.SH近20日+31.34%，显示管线利好已被提前交易。
- 公司公告Soficitinib白癜风II期部分达到主要终点，24周F-VASI较基线改善显著优于安慰剂，安全性未见新增信号。市场反应:公告时港股和A股已收盘，无法盘中交易。
- FierceBiotech转载并强调InnoCare将在白癜风适应症推进III期，同时指出Takeda、BMS、Incyte等竞争背景。
关键理由
- 事件本身偏正面：Soficitinib在非节段型白癜风II/III研究的II期部分达到主要终点，且公司称安全性良好、将推进III期。
- 但这是白癜风II期读数，距离商业化仍有III期、注册、医保和竞争格局验证；相对公司2025年约23.75亿元收入和约52亿元A股市值/28亿港元港股市值，短期业绩增量仍无法落地。
- 诺诚健华（09969.HK/688428.SH）近20日分别已涨约35%/31%，且前一日AD III期成功已显著重定价，同一分子的白癜风II期追加读数更像管线确认而非新的强交易窗口。
主要风险
- 若后续完整数据在学会上显示疗效显著优于同类且安全性强，或出现大额BD/授权，管线估值可能继续上修。
- 创新药板块情绪较强，短线可能被连续临床利好推动高开，但高开追入容易遇到兑现。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-16 · 影响 weakens
未见本次读数的新增安全性负面，但口服JAK/TYK2类药物仍有感染、脂质、潜在恶性肿瘤等类别安全性关注。
检索:InnoCare soficitinib safety adverse JAK TYK2 risk vitiligo phase 2 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-16 · 影响 weakens
白癜风已有Incyte Opzelura，且Takeda、BMS等TYK2/JAK相关项目在研，竞争和差异化仍需完整数据证明。
检索:vitiligo TYK2 inhibitor competition Opzelura Takeda zasocitinib Sotyktu 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-07-16 · 影响 supports
内部库命中券商点评称ICP-332连续两日数据利好、上调商业化风险调整概率和出海潜力；但这也说明事件已被机构快速解读，且更偏估值概率上修。
检索:诺诚健华 ICP-332 soficitinib 白癜风 适应症 收入 销售 商业化 2026 原文 ↗
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,104 字
A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.
Incyte has FDA approval for Opzelura, which inhibits all JAKs and TYK2, in the autoimmune skin disorder vitiligo. Developers of TYK2 inhibitors have recognized the opportunity, with Takeda running a phase 2 trial of zasocitinib in the indication and InnoCare assessing soficitinib in a phase 2/3 study. Researchers are testing Bristol Myers Squibb’s Sotyktu in the indication in a midphase investigator-initiated study.
Thursday, InnoCare furthered its pursuit of the market by publishing topline data from the phase 2 part of its trial. Run from sites in China, the study evaluated the effect of 24 weeks of daily oral dosing on the Facial Vitiligo Area Scoring Index (F-VASI), a measure of disease severity.
At Week 24, F-VASI changed by 41.2% on the high dose of soficitinib, compared to 38.8% on the low dose and 2.2% on placebo. Both soficitinib doses performed significantly better than placebo, achieving the trial’s primary endpoint.
InnoCare has yet to share further efficacy data, and only provided a high-level overview of its safety and tolerability results. The safety profile was favorable and consistent with previous studies, the company said. Soficitinib was reportedly well tolerated and no new safety signals were uncovered. InnoCare plans to share detailed safety and efficacy results at a scientific congress or in an academic journal.
The phase 2/3 vitiligo study is part of a multi-front push to explore the potential of soficitinib, also called ICP-332. InnoCare is running mid- to late-phase trials in atopic dermatitis, chronic spontaneous urticaria, plaque psoriasis and prurigo nodularis.
In parallel, the biotech is testing another TYK2 drug candidate, ICP-488, in a phase 2 cutaneous lupus erythematosus trial and a phase 3 plaque psoriasis study. Soficitinib is a TYK2 JH1 inhibitor, while ICP-488 binds the JH2 domain. Meanwhile, BMS’ Sotyktu and Takeda’s zasocitinib bind JH2.
Incyte has FDA approval for Opzelura, which inhibits all JAKs and TYK2, in the autoimmune skin disorder vitiligo. Developers of TYK2 inhibitors have recognized the opportunity, with Takeda running a phase 2 trial of zasocitinib in the indication and InnoCare assessing soficitinib in a phase 2/3 study. Researchers are testing Bristol Myers Squibb’s Sotyktu in the indication in a midphase investigator-initiated study.
Thursday, InnoCare furthered its pursuit of the market by publishing topline data from the phase 2 part of its trial. Run from sites in China, the study evaluated the effect of 24 weeks of daily oral dosing on the Facial Vitiligo Area Scoring Index (F-VASI), a measure of disease severity.
At Week 24, F-VASI changed by 41.2% on the high dose of soficitinib, compared to 38.8% on the low dose and 2.2% on placebo. Both soficitinib doses performed significantly better than placebo, achieving the trial’s primary endpoint.
InnoCare has yet to share further efficacy data, and only provided a high-level overview of its safety and tolerability results. The safety profile was favorable and consistent with previous studies, the company said. Soficitinib was reportedly well tolerated and no new safety signals were uncovered. InnoCare plans to share detailed safety and efficacy results at a scientific congress or in an academic journal.
The phase 2/3 vitiligo study is part of a multi-front push to explore the potential of soficitinib, also called ICP-332. InnoCare is running mid- to late-phase trials in atopic dermatitis, chronic spontaneous urticaria, plaque psoriasis and prurigo nodularis.
In parallel, the biotech is testing another TYK2 drug candidate, ICP-488, in a phase 2 cutaneous lupus erythematosus trial and a phase 3 plaque psoriasis study. Soficitinib is a TYK2 JH1 inhibitor, while ICP-488 binds the JH2 domain. Meanwhile, BMS’ Sotyktu and Takeda’s zasocitinib bind JH2.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。